CVS Group Reports 5.9% Revenue Growth for Fiscal Year 2026

CVS Group, the UK-based veterinary services giant, reported a robust performance for the fiscal year ended June 30, 2026, with total revenue increasing by 5.9% to £712.8 million. This growth was primarily driven by the company's expansion in Australia, compensating for more modest growth in the highly competitive UK market. These results are anticipated to have a positive impact on the company's earnings per share and overall market valuation, serving as a key indicator for investors.

According to the company's trading update, like-for-like sales growth stood at 2.1%. While this figure remained below CVS Group's medium-term target range of 4% to 8%, it represents a significant improvement compared to the 0.2% growth recorded in the previous fiscal year. Operations in the United Kingdom generated £633.7 million in revenue, with growth in this market hovering around 2%. In contrast, Australian operations posted a remarkable 51.8% increase, contributing £79.1 million in revenue and now accounting for 11% of the group's total revenue.

Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) reached £141.5 million, closely matching market expectations of £141.6 million. The EBITDA margin was reported at 19.9%, falling within the company's stated medium-term guidance range of 19% to 23%. The company continued its international expansion strategy by acquiring six new practices in Australia during the fiscal year, bringing its footprint in the region to 35 clinics.

These financial developments underscore CVS Group's resilient performance despite a general economic slowdown in the UK and weaker consumer confidence. The robust growth in the Australian market, in particular, highlights the success of the company's geographical diversification strategy, acting as a buffer against competitive pressures and challenging consumer demand in the UK. Although net debt (excluding leases) increased to £199.6 million, the leverage ratio of 1.63 times net debt to EBITDA remained comfortably below the company's target ceiling of 2.0 times.

CVS Group completed £11.7 million in share buybacks by the end of FY26 as part of a £50 million program announced in May 2026. The remaining £38.3 million authorization for buybacks is valid through November. The company anticipates annual capital expenditure to be approximately £30 million going forward, placing it at the lower end of its previous £30 million to £40 million range. This disciplined approach reflects the company's commitment to maintaining financial health and enhancing shareholder value.

Analysts and market observers maintain positive medium to long-term growth expectations for CVS Group, driven by strong acquisition potential in Australia and prospective new acquisitions in the UK following the conclusion of the Competition and Markets Authority (CMA) process. The company boasts a solid balance sheet with £132 million in undrawn credit facilities and £18.4 million in cash, providing significant financial flexibility for future growth and strategic investments.